Bobby Tang

Paediatric Ophthalmologist | Clinical Advisor and Investor at PeriVision | HSE National Fellow for Innovation & Change

๐Ÿ“ Ireland๐Ÿ”„ Updated September 2026๐Ÿ’ผ 1 investments๐Ÿ“… 5 years investing๐Ÿ—“ Last invested Jun 2021
Angel investor๐ŸŒ Ireland
1
Total investments
0
Early stage
0
Mid stage
0
Late stage
5y
Years active

Portfolio

1 investments ยท sorted by recency
All investments
Early stage
Mid stage
Late stage
Clinical Advisor & Investor
Jun 2021
Vision is the most dominant of our senses. Yet, 2.2 billion people suffer from vision impairments of which 50% could be prevented or cured. And this number is growing due to our ageing populations and modern lifestyles. At the same time healthcare systems have limited resources. Eye care lags behind in the digital transformation and novel technology is not fully leveraged. As a result, people lose vision that do not have to. We combine AI algorithms, virtual reality and cloud computing to build the next generation systems to test visual function. We improve workflow efficiency and provide deeper clinical insight into eye diseases. To leverage these technologies fully, we take a disease-centric approach. The first condition we target is glaucoma. We address the large unmet need for more efficient and effective monitoring of 80M patients worldwide.
Experience ยท 1 entries
All (1)
Investments (1)
2021
Clinical Advisor & Investor
Jun 2021
Vision is the most dominant of our senses. Yet, 2.2 billion people suffer from vision impairments of which 50% could be prevented or cured. And this number is growing due to our ageing populations and modern lifestyles. At the same time healthcare systems have limited resources. Eye care lags behind in the digital transformation and novel technology is not fully leveraged. As a result, people lose vision that do not have to. We combine AI algorithms, virtual reality and cloud computing to build the next generation systems to test visual function. We improve workflow efficiency and provide deeper clinical insight into eye diseases. To leverage these technologies fully, we take a disease-centric approach. The first condition we target is glaucoma. We address the large unmet need for more efficient and effective monitoring of 80M patients worldwide.